XRPN (Armada Acquisition Corp. II) jumped +25.14% during regular trading hours on Sept 29, climbing from a $10.58 prior close to $13.24. The catalyst is the Sept 30 special shareholder vote on the merger with Evernorth, which would bring a managed XRP treasury (~473M XRP) onto Nasdaq under the XRPN ticker.

IDT shares surged +10.51% during regular trading, climbing from a $69.56 prior close to roughly $76.87. Primary catalyst: record fourth-quarter and full-year fiscal 2026 results reported after Monday's close, plus upbeat fiscal 2027 guidance.

Different scale and sector focus: ARAY is a radiation therapy equipment maker, while ILMN is a genomics and DNA-sequencing leader. Diverging momentum: Illumina is in a strong uptrend with accelerating revenue growth, while Accuray is managing a revenue decline and a balance-sheet turnaround.

Both are speculative, small-cap biotech/pharma names trading on the Nasdaq with sub-$1-to-low-single-digit share prices and elevated volatility. FLNA is a clinical-stage developer of CNS (central nervous system) therapies that has faced an FDA clinical hold and a Nasdaq listing-compliance notice.

APUS is an early-stage company that has recently pivoted toward digital-asset (bitcoin treasury) operations, while DERM is a commercial-stage dermatology pharmaceutical company with marketed, revenue-generating products. DERM generates recurring revenue from eight branded, FDA (U.S. Food and Drug Administration)-approved drugs; APUS reported no biopharmaceutical revenue and disclosed a going-concern risk in its most recent annual filing.

SMX shares have fallen roughly 57% over the past 30 days, declining from about $16.61 (closing level on August 28) to about $7.22, as selling accelerated sharply in late September. The stock is down approximately 47% over the trailing three-month period, extending a longer pattern of decline for this micro-cap, Nasdaq-listed company.

DELL is levered to the AI-server build-out, with a record backlog and sharply raised revenue guidance; NTAP offers steadier, higher-margin exposure to data storage and cloud. DELL is growing much faster on the top line but carries a lower margin profile and higher debt; NTAP grows more slowly but is highly profitable and returns substantial cash to shareholders.

EVGN is trading up +10.42% intraday (to roughly $0.42), rebounding during the regular session from a prior close of $0.38. The gain follows yesterday's -8.59% post-earnings selloff after Q2 2026 results reported EPS of -$0.63 and revenue down 76.4% year-over-year to $670K.

KMRK climbed +15.05% to roughly $1.07 in regular-session trading, up from a prior close near $0.93. The move occurred during normal market hours, not premarket or after-hours.

DXST is trading up +64.62% during regular market hours, around $3.21 versus a prior close of $1.95. The move follows an overnight after-hours spike of roughly +148% to about $3.97, triggered by an SEC filing revealing Chairman Dingxin Sun raised his voting stake to 90.5% through a private placement.

BGIN is up +22.70% intraday to about $2.27, versus a previous-session close of $1.85. The advance occurred during regular market hours (around midday ET), not in premarket or after-hours trading.

APUS is down -20.97% intraday, trading near $5.05 versus the prior session's close of $6.39, during regular NYSE American hours. The decline extends a sharp reversal after a parabolic spike: shares surged +114.85% on Sep 24 and +47.36% on Sep 25 on the MindWave Bitcoin-treasury narrative.

INUV is trading down about -5.26% to roughly $0.54 during the regular session, versus its prior close of $0.57. The decline occurred in normal market hours, not premarket or after-hours, on relatively light volume typical of this small-cap name.

JAGX is down -12.96% to $5.24 in regular trading, extending a slide from the prior session's $6.02 close. The drop follows an earlier squeeze that briefly sent shares up as much as +2,261% intraday on crofelemer pipeline and FDA fee-waiver news.

IOVA is up +36.67% in the regular session, surging from a prior close of $10.99 to about $15.02 after gapping higher in premarket trading. Primary catalyst: the company raised its full-year 2026 revenue guidance to $410–$420 million, up from $350–$370 million.

CZR is a large-cap casino operator with a market value of roughly $6 billion and more than $11 billion in debt, while INSE is a small-cap gaming technology supplier valued near $200 million. Caesars has posted strong year-to-date share gains but continues to report net losses, weighed down by high interest costs and uneven Las Vegas trends.

NNVC fell -11.33% during regular trading, sliding from a $1.50 prior close to about $1.33. The decline followed the filing of its annual report, with EPS of -$0.10 missing the -$0.09 estimate.

ACET (Adicet Bio) is a clinical-stage cell therapy developer that recently reported positive Phase 1 lupus data, yet its shares remain highly volatile. VIR (Vir Biotechnology) swung to a quarterly profit on a major collaboration payment and carries a near-term pivotal hepatitis delta readout.

CCB is a Washington-based community bank with a fast-growing Banking-as-a-Service (BaaS) arm, while LOB is a North Carolina lender built around U.S. Small Business Administration (SBA) loans and digital business banking. Recent market activity has diverged sharply: LOB has outperformed the broader market year-to-date, whereas CCB has lagged significantly.

KPTI fell roughly -21% during regular trading, sliding from a $1.62 prior close to about $1.28. The decline extends a prolonged downtrend rather than a single new headline, reflecting acute liquidity concerns.